FDA Chief Counsel Addresses Staff Turnover, Device Bans
This article was originally published in The Gray Sheet
Executive Summary
Staff turnover in FDA's Office of the Chief Counsel is a positive, says the agency's top lawyer Elizabeth Dickinson. The chief counsel also discussed recent device bans, off-label communication policy efforts and the agency’s ongoing transparency initiative at the annual Food & Drug Law Institute conference.
You may also be interested in...
Public Supports US FDA Ban On Electroshock Devices
Electrical stimulation devices are used to discourage harmful behavior at one Massachusetts school. Commenters from a wide range of patient advocacy groups and state organizations wrote to support FDA’s proposed ban on ESDs, saying it’s abusive and ineffective.
In Case You Missed It: Top 10 Gray Sheet Stories In May
Our reporting on a halted Medtronic stent-graft trial was the most popular online story last month in The Gray Sheet. Also attracting significant attention in May: coverage of the big regulatory changes afoot in Europe, and the growing efforts by FDA leadership to push forward with an envisioned "national evaluation system" for devices.
Vascular Solutions Case (Partially) Points Way Forward For Off-Label Marketing
Attorneys involved with a recent court ruling favoring Vascular Solutions believe the verdict might give manufacturers more latitude to engage in truthful, non-misleading, off-label speech. But caution is necessary.